3-Hydroxy-3-methylglutaryl-coenzyme A (
HMG-CoA) lyase deficiency is usually clinically evident during infancy and is characterized by vomiting, hypotonia, lethargy, metabolic acidosis, non-ketotic hypoglycemia, and Reyelike syndrome.
Pleiotropic effects of
HMG-CoA reductase inhibitors.
A bioactive compound known as lovastatin, found in high concentrations in the extract, successfully inhibited
HMG-CoA reductase in an experiment designed to test the enzyme's activity.
Atorvastatin is a synthetic analogue of
HMG-CoA, highly effective in reducing LDL-C levels and triglycerides10.
Inhibition of converting 3-hydroxy-3-methylglutaryl-coenzyme A (
HMG-coA) to mevalonate (initiating step in cholesterol biosynthesis pathway) accomplished by
HMG-coA reductase is the target of drug development for hypercholesterolemic patients.
Further, the studies conducted worldwide so far on antilipidemic activity of authenticated Ceylon cinnamon did not address its effect on
HMG-CoA reductase, cholesterol esterase, and cholesterol micellization inhibitory activities and bile acid binding.
Statins are
HMG-CoA inhibitors (hydroxymethylglutaryl/coenzyme A) and they lower the cholesterol levels by competitively inhibiting the
HMG-CoA reductase, the final pathway in cholesterol biosynthesis [4, 8].
HMG-CoA reductase (HMGCR), which catalyzes the conversion of
HMG-CoA to mevalonate, is the rate-limiting enzyme in cholesterol biosynthesis.
Statins are drugs that block a cholesterol-producing enzyme in the liver called
HMG-CoA reductase.
Therapeutic approaches of dyslipidemia currently rely on the use of statins, pharmacological inhibitors of cholesterol biosynthesis that act on the key enzyme 3-hydroxy-3-methylglutaryl-Co-enzyme A (
HMG-CoA) reductase (Athyros et al.
There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (
HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine).
Statins might help prevent CRC through
HMG-CoA reductase inhibition and other mechanisms, according to the researchers.